The University of New South Wales – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 34
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: U4E8AF0B6F8EN
Leaflet:

Download PDF Leaflet

The University of New South Wales – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “The University of New South Wales – Developmental Therapeutics Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • The University of New South Wales – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of The University of New South Wales human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of The University of New South Wales with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the The University of New South Wales’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate The University of New South Wales’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of The University of New South Wales in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the The University of New South Wales’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with The University of New South Wales.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of The University of New South Wales and identify potential opportunities in those areas.
The University of New South Wales Snapshot
Key Information
Key Facts
The University of New South Wales – Research and Development Overview
Key Therapeutic Areas
The University of New South Wales – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
The University of New South Wales – Pipeline Products Glance
The University of New South Wales – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The University of New South Wales Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
The University of New South Wales – Drug Profiles
alemtuzumab + arsenic trioxide + azacitidine + busulfan + clofarabine + cytarabine + daunorubicin hydrochloride + fludarabine phosphate + gemtuzumab ozogamicin + melphalan + tipifarnib
  Product Description
  Mechanism of Action
  R&D Progress
alemtuzumab + arsenic trioxide + azacitidine + busulfan + clofarabine + cytarabine + daunorubicin hydrochloride + fludarabine phosphate + gemtuzumab ozogamicin + melphalan + tipifarnib
  Product Description
  Mechanism of Action
  R&D Progress
D-Cycloserine
  Product Description
  Mechanism of Action
  R&D Progress
Escitalopram (Lexapro)
  Product Description
  Mechanism of Action
  R&D Progress
Modafinil
  Product Description
  Mechanism of Action
  R&D Progress
nicotine transdermal patch/lozenge
  Product Description
  Mechanism of Action
  R&D Progress
Oxytocin
  Product Description
  Mechanism of Action
  R&D Progress
The University of New South Wales – Pipeline Analysis
The University of New South Wales – Pipeline Products by Therapeutic Class
The University of New South Wales Pipeline Products By Target
The University of New South Wales – Pipeline Products by Route of Administration
The University of New South Wales – Pipeline Products by Molecule Type
The University of New South Wales - Dormant Projects
The University of New South Wales – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 34

LIST OF TABLES

The University of New South Wales – Pipeline by Therapy Area and Indication, 2010
The University of New South Wales – Pipeline by Stage of Development, 2010
The University of New South Wales – Monotherapy Products in Pipeline, 2010
The University of New South Wales – Combination Treatment Modalities in Pipeline, 2010
The University of New South Wales – Phase III, 2010
The University of New South Wales - Phase II, 2010
The University of New South Wales - Pipeline By Therapeutic Class, 2010
The University of New South Wales - Pipeline By Target, 2010
The University of New South Wales – Pipeline By Route of Administration, 2010
The University of New South Wales – Pipeline By Molecule Type, 2010
The University of New South Wales - Dormant Developmental Projects, 2010 31

LIST OF FIGURES

The University of New South Wales – Pipeline by Therapy Area and Indication, 2010
The University of New South Wales – Pipeline by Stage of Development, 2010
The University of New South Wales – Monotherapy Products in Pipeline, 2010
The University of New South Wales – Combination Treatment Modalities in Pipeline, 2010
The University of New South Wales – Pipeline By Therapeutic Class, 2010
The University of New South Wales - Pipeline By Target, 2010
The University of New South Wales – Pipeline By Route of Administration, 2010
The University of New South Wales – Pipeline By Molecule Type, 2010 30

Ask Your Question

The University of New South Wales – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: